Based on the accumulated preclinical and clinical data, CD19 has been viewed as a promising target for application in multi-target cellular immunotherapy in MM patients, notably in the occurrence of relapses and resistance to BCMA-targeted treatment [138]. This evidence concerns the gene CD19 and Miyoshi myopathy.